Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/17385
Title: Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.
Authors: Mattsson, Niklas;Groot, Colin;Jansen, Willemijn J;Landau, Susan;Villemagne, Victor;Engelborghs, Sebastiaan;Mintun, Mark;Lleo, Alberto;Molinuevo, José Luis;Jagust, William;Frisoni, Giovanni B;Ivanoiu, Adrian;Chételat, Gaël;Resende de Oliveira, Catarina;Rodrigue, Karen M;Kornhuber, Johannes;Wallin, Anders;Klimkowicz-Mrowiec, Aleksandra;Kandimella, Ramesh;Popp, Julius;Aalten, Pauline P;Aarsland, Dag;Alcolea, Daniel;Almdahl, Ina S;Baldeiras, Inês;van Buchem, Mark A;Cavedo, Enrica;Chen, Kewei;Cohen, Ann D;Förster, Stefan;Fortea, Juan;Frederiksen, Kristian S;Freund-Levi, Yvonne;Gill, Kiran Dip;Gkatzima, Olymbia;Grimmer, Timo;Hampel, Harald;Herukka, Sanna-Kaisa;Johannsen, Peter;van Laere, Koen;de Leon, Mony;Maier, Wolfgang;Marcusson, Jan;Meulenbroek, Olga;Møllergård, Hanne M;Morris, John C;Mroczko, Barbara;Nordlund, Arto;Prabhakar, Sudesh;Peters, Oliver;Rami, Lorena;Rodríguez-Rodríguez, Eloy;Roe, Catherine M;Rüther, Eckart;Santana, Isabel;Schröder, Johannes;Seo, Sang W;Soininen, Hilkka;Spiru, Luiza;Stomrud, Erik;Struyfs, Hanne;Teunissen, Charlotte E;Verhey, Frans R J;Vos, Stephanie J B;van Waalwijk van Doorn, Linda J C;Waldemar, Gunhild;Wallin, Åsa K;Wiltfang, Jens;Vandenberghe, Rik;Brooks, David J;Fladby, Tormod;Rowe, Christopher C;Drzezga, Alexander;Verbeek, Marcel M;Sarazin, Marie;Wolk, David A;Fleisher, Adam S;Klunk, William E;Na, Duk L;Sánchez-Juan, Pascual;Lee, Dong Young;Nordberg, Agneta;Tsolaki, Magda;Camus, Vincent;Rinne, Juha O;Fagan, Anne M;Zetterberg, Henrik;Blennow, Kaj;Rabinovici, Gil D;Hansson, Oskar;van Berckel, Bart N M;van der Flier, Wiesje M;Scheltens, Philip;Visser, Pieter Jelle;Ossenkoppele, Rik
Affiliation: Clinical Memory Research Unit, Clinical Sciences Malmö, Lund University, Lund, Sweden
Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands
Helen Wills Neuroscience Institute, University of California, Berkeley, CA, USA
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium
Avid Radiopharmaceuticals, Philadelphia, PA, USA
Neurology Department, Hospital de Sant Pau, Barcelona, Spain
Alzheimer's Disease and Other Cognitive Disorders Unit, IDIBAPS, Clinic University Hospital, Barcelona, Spain
Memory Clinic and LANVIE- Laboratory of Neuroimaging of Aging, University Hospitals, and University of Geneva, Geneva, Switzerland
Laboratory of Alzheimer's Neuroimaging and Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
Memory Clinic and Neurochemistry Laboratory, Saint Luc University Hospital, Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium
Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France
Center for Neuroscience and Cell Biology, Faculty of Medicine, Centro Hospitalar e Universitário de Coimbra, Portugal
Center for Vital Longevity, School of Behavioral and Brain Sciences, The University of Texas at Dallas, Dallas, TX, USA
Department of Psychiatry and Psychotherapy, Friedrich-Alexander University of Erlangen- Nuremberg, Erlangen, Germany
Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
Jagiellonian University College of Medicine, Krakow, Poland
Postgraduate Institute of Medical Education and Research (PGIMER), Department of Biochemistry, Research Block-A, Chandigarh, India
Department of Psychiatry, Service of Old Age Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland
Center for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
Department of Neurology, Akershus University Hospital, Lørenskog, Norway
Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
AXA Research Fund & UPMC Chair, Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Inserm, CNRS, Institut du Cerveau et de la Moelle Épinière (ICM), Département de Neurologie, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Paris, France
Banner Alzheimer's Institute, Phoenix, AZ, USA
University of Pittsburgh School of Medicine, Department of Psychiatry, Pittsburgh, PA, USA
Department of Nuclear Medicine, Technische Universitaet München, Munich, Germany
Danish Dementia Research Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Department of Geriatrics, Karolinska University Hospital Huddinge, Section of Clinical Geriatrics, Institution of NVS, Karolinska Institutet, Stockholm, Sweden
Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitaet München, Munich, Germany
Department of Psychiatry, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Ludwig-Maximilian University, Munich, Germany
Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland
Memory Clinic, Danish Dementia Research Center, Rigshospitalet, Copenhagen, Denmark
Department of Imaging and Pathology, Catholic University Leuven, Leuven, Belgium
School of Medicine, Center for Brain Health, New York University, New York, NY, USA
Department of Psychiatry and Psychotherapy, University of Bonn, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Geriatric Medicine, Department of Clinical and Experimental Medicine, University of Linköping, Linköping, Sweden
Department of Geriatric Medicine, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands
Knight Alzheimer's Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Department of Neurodegeneration Diagnostics, Leading National Research Centre in Białystok (KNOW), Medical University of Białystok, Białystok, Poland
Department of Neurology, Research Block-A, Chandigarh, India
Department of Psychiatry and Psychotherapy, Charité Berlin, German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
Neurology Service, Universitary Hospital Marqués de Valdecilla, CIBERNED, IDIVAL, Santander, Spain
Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, Göttingen, Germany
Sektion Gerontopsychiatrie, Universität Heidelberg, Heidelberg, Germany
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Department of Geriatrics-Gerontology-Gerontopsychiatry, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands
Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands
Department of Laboratory Medicine, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands
Laboratory for Cognitive Neurology and Alzheimer Research Centre KU Leuven, Catholic University Leuven, Leuven, Belgium
Division of Neuroscience, Medical Research Council Clinical Sciences Centre, Imperial College London, London, UK
Department of Nuclear Medicine, University of Cologne, Cologne, Germany..
Neurologie de la Mémoire et du Langage, Centre Hospitalier Sainte-Anne, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Eli Lilly, Indianapolis, IN, USA
Department of Neurosciences, University of California, San Diego, CA, USA
Department of Neuropsychiatry, Seoul National University, College of Medicine, Seoul, South Korea
Department NVS, Center for Alzheimer Research, Translational Alzheimer Neurobiology, Karolinska Institutet and Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden
CHRU de Tours, CIC INSERM 1415, INSERM U930, Université François Rabelais de Tours, Tours, France
Turku PET Centre and Division of Clinical Neurosciences Turku, University of Turku and Turku University Hospital, Turku, Finland
Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute, London, UK
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
Sweden and Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA, USA
Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands
Department of Radiology and Nuclear Medicine, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, the Netherlands
Issue Date: 27-Mar-2018
EDate: 2018
Citation: Alzheimer's & dementia 2018; online first: 27 March
Abstract: Apolipoprotein E (APOE) ε4 is the major genetic risk factor for Alzheimer's disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid β (Aβ) pathology. We included 3451 Aβ+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE ε4 prevalence in relation to age, sex, education, and geographical location. The APOE ε4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in Aβ+ cognitively normal and Aβ+ mild cognitive impairment (P < .05) but not in Aβ+ AD dementia (P = .66). The prevalence was highest in Northern Europe but did not vary by sex or education. The APOE ε4 prevalence in AD was higher than that in previous studies, which did not require presence of Aβ pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location.
URI: http://ahro.austin.org.au/austinjspui/handle/1/17385
DOI: 10.1016/j.jalz.2018.02.009
ORCID: 0000-0003-3910-2453
PubMed URL: 29601787
Type: Journal Article
Subjects: APOE
Age
Alzheimer's disease
Amyloid
CSF
Education
Geographical location
Mild cognitive impairment
PET
Prevalence
Sex
Subjective cognitive decline
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.